Effect Of Dexmedetomidine On Cerebral Vasospasm And Associated Biomarkers In A Rat Subarachnoid Hemorrhage Model | 102904
Journal of Neurological Disorders
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Background & Aim: The ?2 adrenergic agonist dexmedetomidine has huge potential for protecting against cerebral vasospasm,
a leading cause of death and disability after Subarachnoid Hemorrhage (SAH). Biomarker assay in SAH is recently emerging
as a tool for predicting vasospasm and outcomes. We investigated the effects of dexmedetomidine on vasospasm with the
assessment of biomarkers in a rat SAH model.
Methods: Male Wistar rats were randomly assigned to sham (n=10), SAH (n=10) or SAH+DEX (n=10) groups. The SAH
and SAH+DEX groups received 0.3 mL injections of autologous blood into the cisterna magna followed by intraperitoneal
injections of normal saline or 10 ?g/kg dexmedetomidine. Forty-eight hours later, neurological deficits as well as the Basilar
Artery (BA) wall thickness and Cross-Sectional Area (CSA) were measured. Cerebrospinal Fluid (CSF) and blood samples
were obtained to assess concentrations of interleukin (IL)-6, C-Reactive Protein (CRP), Endothelin (ET)-1 and S100-? using
enzyme-linked immunosorbent assays.
Results: The SAH and SAH+DEX groups exhibited deteriorated neurological function and structural and morphological
BA vasospasm. The SAH+DEX group showed an improved neurological function score (52% decrease), a 10% reduction in
wall thickness and a larger BA CSA (by 157%). Compared to the sham group, CSF levels of IL-6 and CRP in the SAH and
SAH+DEX groups, as well as serum IL-6 and CRP levels in the SAH group were significantly elevated. The SAH+DEX group
showed significantly lower CSF IL-6 levels compared to the SAH group. Serum and CSF levels of ET-1 and S100-? were similar
among all groups.
Conclusion: Dexmedetomidine administration reduced the severity of cerebral vasospasm and improved neurological
function in SAH rats, which may be closely linked to reduced CSF IL-6 level.
Dong Woo Han has completed his PhD in 2005 from Soonchunhyang University College of Medicine, South Korea. He is a Professor in the Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, South Korea. He has published more than 60 papers in reputed journals and has been serving as an Editorial Board Member of Korean Society of Anesthesiologists.